Display options
Cite
Brust AK, Ulbrich HK, Seigel GM, et al. Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells. Biomark Insights. 2008;3:387-402doi: 10.4137/bmi.s692.
Brust, A. K., Ulbrich, H. K., Seigel, G. M., Pfeiffer, N., & Grus, F. H. (2008). Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells. Biomarker insights, 3387-402. https://doi.org/10.4137/bmi.s692
Brust, Anja-Kristina, et al. "Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells." Biomarker insights vol. 3 (2008): 387-402. doi: https://doi.org/10.4137/bmi.s692
Brust AK, Ulbrich HK, Seigel GM, Pfeiffer N, Grus FH. Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells. Biomark Insights. 2008 Jul 08;3:387-402. doi: 10.4137/bmi.s692. PMID: 19578520; PMCID: PMC2688370.
Copy Download .nbib Format: NLM
Share it on

Biomark Insights. 2008 Jul 08;3:387-402. doi: 10.4137/bmi.s692.

Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.

Biomarker insights

Anja-Kristina Brust, Holger K Ulbrich, Gail M Seigel, Norbert Pfeiffer, Franz H Grus

Affiliations

  1. Department of Ophthalmology, Johannes Gutenberg University of Mainz, Germany.

PMID: 19578520 PMCID: PMC2688370 DOI: 10.4137/bmi.s692

Abstract

Glaucoma is characterized by a loss of retinal ganglion cells (RGC) which is associated with a decrease of visual function. Neuroprotective agents as a new therapeutic strategy could prevent the remaining neurons from apoptotic cell death. Previous studies have shown the involvement of the Cyclooxygenase (COX)-2 signalling in the apoptotic death of neurons. Herein we investigated the neuroprotective effect of COX-1/COX-2- and selective COX-2- inhibitors on apoptotic. R28, a neuroretinal cell line and determined the PGE(2) levels by ELISA. Furthermore we investigated differences in protein expression in the cells after exposure to elevated pressure compared to untreated cells by ProteinChip analysis.In addition, a protein profiling study of the cells after exposure to elevated pressure was performed. The protein expression profiles were measured by SELDI-TOF (Surface Enhanced Laser Desorption/Ionization-time of flight) Protein Chips. The protein identification was performed by mass spectrometry (MS).It could be shown that COX-2 inhibition significantly prevented the cells from apoptosis and reduced the PGE(2) concentrations. Selective COX-2 inhibitors were significant more potent than non-selective inhibitors or COX-1 inhibitors. We found differently expressed protein patterns in neuroretinal cells cultured at atmospheric pressure compared to those cells exposed to elevated pressure with or without celecoxib respectively. We identified three biomarkers, ubiquitin, HSP10 and NDKB, which were differently expressed in the groups. However, our data indicates a distinct neuroprotective effect of COX-2 inhibition. The local treatment with selective COX-2 inhibitors might provide an innovative strategy of therapeutic intervention for glaucoma.

References

  1. Biochem Biophys Res Commun. 1998 Mar 27;244(3):819-24 - PubMed
  2. Annu Rev Pharmacol Toxicol. 1998;38:97-120 - PubMed
  3. Br J Ophthalmol. 1996 May;80(5):389-93 - PubMed
  4. Mol Vis. 1996 Apr 24;2:2 - PubMed
  5. Adv Exp Med Biol. 2001;487:169-86 - PubMed
  6. J Clin Invest. 2006 Jan;116(1):4-15 - PubMed
  7. Neurology. 1996 Aug;47(2):425-32 - PubMed
  8. Nat Med. 2001 Apr;7(4):414-5 - PubMed
  9. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6500-5 - PubMed
  10. Neurochem Int. 1994 Apr;24(4):395-8 - PubMed
  11. Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2625-39 - PubMed
  12. In Vitro Cell Dev Biol Anim. 1996 Feb;32(2):66-8 - PubMed
  13. Mol Vis. 2000 Aug 31;6:157-63 - PubMed
  14. Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2616-24 - PubMed
  15. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):968-76 - PubMed
  16. Int J Biochem Cell Biol. 2003 May;35(5):547-52 - PubMed
  17. J Glaucoma. 2002 Dec;11(6):474-80 - PubMed
  18. Neuron. 1993 Aug;11(2):371-86 - PubMed
  19. Prog Brain Res. 1998;118:281-91 - PubMed
  20. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1294-9 - PubMed
  21. Brain Res Mol Brain Res. 2000 Jun 23;79(1-2):169-73 - PubMed
  22. Nat Med. 2006 Feb;12(2):225-9 - PubMed
  23. J Neurotrauma. 2002 May;19(5):627-38 - PubMed
  24. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10954-9 - PubMed
  25. J Pharmacol Exp Ther. 2000 May;293(2):417-25 - PubMed
  26. Arch Ophthalmol. 2006 Feb;124(2):217-25 - PubMed
  27. Br J Ophthalmol. 2000 Apr;84(4):423-8 - PubMed
  28. Biochem Biophys Res Commun. 2002 Aug 30;296(4):970-5 - PubMed
  29. Lancet. 1999 Nov 20;354(9192):1803-10 - PubMed
  30. J Neurobiol. 1992 Nov;23(9):1261-76 - PubMed
  31. FASEB J. 1998 Sep;12(12):1063-73 - PubMed
  32. Brain Res. 2006 May 1;1086(1):191-200 - PubMed
  33. J Neurotrauma. 2002 Jan;19(1):1-15 - PubMed
  34. Biochem Pharmacol. 2004 Jul 15;68(2):341-50 - PubMed
  35. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S116-24 - PubMed
  36. Curr Med Res Opin. 2002;18(8):503-11 - PubMed
  37. J Biol Chem. 1996 Dec 27;271(52):33157-60 - PubMed
  38. Invest Ophthalmol Vis Sci. 2005 Mar;46(3):863-76 - PubMed
  39. Bioorg Med Chem Lett. 1999 Nov 15;9(22):3181-6 - PubMed
  40. Br J Ophthalmol. 2001 Oct;85(10):1252-9 - PubMed
  41. Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30 - PubMed
  42. J Med Chem. 1997 Apr 25;40(9):1347-65 - PubMed

Publication Types